Molecular imaging to track Parkinson's disease and atypical parkinsonisms: New imaging frontiers

Antonio P Strafella¹, Nicolaas I Bohnen², Joel S Perlmutter³, David Eidelberg⁴, Nicola Pavese⁵, Thilo Van Eimeren⁶, Paola Piccini⁷, Marios Politis⁸, Stephane Thobois⁹, Roberto Ceravolo¹⁰, Makoto Higuchi¹¹, Valtteri Kaasinen¹², Mario Masellis¹³, M Cecilia Peralta¹⁴, Ignacio Obeso¹⁵, Jose Ángel Pineda-Pardo¹⁵, Roberto Cilia¹⁶, Benedicte Ballanger¹⁷, Martin Niethammer⁴, Jon A Stoessl¹⁸; IPMDS-Neuroimaging Study Group¹

Affiliations

¹ Morton and Gloria Shulman Movement Disorder Unit & E.J. Safra Parkinson Disease Program, Neurology Div/Dept. Medicine, Toronto Western Hospital, UHN; Krembil Research Institute, UHN; Research Imaging Centre, Campbell Family Mental Health Research Institute, CAMH, University of Toronto, Ontario, Canada.
² University of Michigan & Veterans Administration Medical Center, Ann Arbor, Michigan, USA.
³ Neurology, Radiology, Neuroscience, Physical Therapy & Occupational Therapy, Washington University in St. Louis, St. Louis, Missouri, USA.
⁴ Center for Neurosciences, The Feinstein Institute for Medical Research, Manhasset, New York, USA.
⁵ Newcastle Magnetic Resonance Centre & Positron Emission Tomography Centre, Newcastle University, Campus for Ageing & Vitality, Newcastle upon Tyne, United Kingdom.
⁶ Multimodal Neuroimaging Group-Department of Nuclear Medicine Department of Neurology-University of Cologne, Institute of Neuroscience and Medicine, Jülich Research Center, German Center for Neurodegenerative Diseases (DZNE), Germany.
⁷ Neurology Imaging Unit, Centre of Neuroinflammation and Neurodegeneration, Division of Brain Sciences, Hammersmith Campus, Imperial College London, United Kingdom.
⁸ Neurodegeneration Imaging Group, Department of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.
⁹ Hospices Civils de Lyon, Hopital Neurologique Pierre Wertheimer, Université Lyon 1; CNRS, Centre de Neurosciences Cognitives, UMR, 5229, Lyon, France.
¹⁰ Department of Clinical and Experimental Medicine, Movement Disorders and Parkinson Center, University of Pisa, Italy.
¹¹ National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan.
¹² Division of Clinical Neurosciences, Turku University Hospital; Department of Neurology, University of Turku; Turku PET Centre, University of Turku, Turku, Finland.
¹³ Cognitive & Movement Disorders Clinic, Sunnybrook Health Sciences Centre; Hurvitz Brain Sciences Research Program, Sunnybrook Research Institute, University of Toronto, Toronto, Ontario, Canada.
¹⁴ Movement Disorder and Parkinson's Disease Program, CEMIC University Hospital, Buenos, Aires, Argentina.
¹⁵ Centro Integral de Neurociencias (CINAC), Hospitales Madrid Puerta del Sur & Centro de Investigación Biomédica en Red, Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.
¹⁶ Parkinson Institute, ASST Gaetano Pini-CTO, Milan, Italy.
¹⁷ INSERM, U1028; CNRS, UMR5292; Lyon Neuroscience Research Center, Neuroplasticity & Neuropathology of Olfactory Perception Team, University Lyon, France.
¹⁸ Pacific Parkinson's Research Centre & National Parkinson Foundation Centre of Excellence, University of British Columbia & Vancouver Coastal Health, Vancouver, British, Columbia, Canada.

PMID: 28150432
DOI: 10.1002/mds.26907

Free article

Review

Molecular imaging to track Parkinson's disease and atypical parkinsonisms: New imaging frontiers

Antonio P Strafella et al. Mov Disord. 2017 Feb.

Free article

. 2017 Feb;32(2):181-192.

doi: 10.1002/mds.26907. Epub 2017 Feb 2.

Authors

Affiliations

¹ Morton and Gloria Shulman Movement Disorder Unit & E.J. Safra Parkinson Disease Program, Neurology Div/Dept. Medicine, Toronto Western Hospital, UHN; Krembil Research Institute, UHN; Research Imaging Centre, Campbell Family Mental Health Research Institute, CAMH, University of Toronto, Ontario, Canada.
² University of Michigan & Veterans Administration Medical Center, Ann Arbor, Michigan, USA.
³ Neurology, Radiology, Neuroscience, Physical Therapy & Occupational Therapy, Washington University in St. Louis, St. Louis, Missouri, USA.
⁴ Center for Neurosciences, The Feinstein Institute for Medical Research, Manhasset, New York, USA.
⁵ Newcastle Magnetic Resonance Centre & Positron Emission Tomography Centre, Newcastle University, Campus for Ageing & Vitality, Newcastle upon Tyne, United Kingdom.
⁶ Multimodal Neuroimaging Group-Department of Nuclear Medicine Department of Neurology-University of Cologne, Institute of Neuroscience and Medicine, Jülich Research Center, German Center for Neurodegenerative Diseases (DZNE), Germany.
⁷ Neurology Imaging Unit, Centre of Neuroinflammation and Neurodegeneration, Division of Brain Sciences, Hammersmith Campus, Imperial College London, United Kingdom.
⁸ Neurodegeneration Imaging Group, Department of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.
⁹ Hospices Civils de Lyon, Hopital Neurologique Pierre Wertheimer, Université Lyon 1; CNRS, Centre de Neurosciences Cognitives, UMR, 5229, Lyon, France.
¹⁰ Department of Clinical and Experimental Medicine, Movement Disorders and Parkinson Center, University of Pisa, Italy.
¹¹ National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan.
¹² Division of Clinical Neurosciences, Turku University Hospital; Department of Neurology, University of Turku; Turku PET Centre, University of Turku, Turku, Finland.
¹³ Cognitive & Movement Disorders Clinic, Sunnybrook Health Sciences Centre; Hurvitz Brain Sciences Research Program, Sunnybrook Research Institute, University of Toronto, Toronto, Ontario, Canada.
¹⁴ Movement Disorder and Parkinson's Disease Program, CEMIC University Hospital, Buenos, Aires, Argentina.
¹⁵ Centro Integral de Neurociencias (CINAC), Hospitales Madrid Puerta del Sur & Centro de Investigación Biomédica en Red, Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.
¹⁶ Parkinson Institute, ASST Gaetano Pini-CTO, Milan, Italy.
¹⁷ INSERM, U1028; CNRS, UMR5292; Lyon Neuroscience Research Center, Neuroplasticity & Neuropathology of Olfactory Perception Team, University Lyon, France.
¹⁸ Pacific Parkinson's Research Centre & National Parkinson Foundation Centre of Excellence, University of British Columbia & Vancouver Coastal Health, Vancouver, British, Columbia, Canada.

PMID: 28150432
DOI: 10.1002/mds.26907

Abstract

Molecular imaging has proven to be a powerful tool for investigation of parkinsonian disorders. One current challenge is to identify biomarkers of early changes that may predict the clinical trajectory of parkinsonian disorders. Exciting new tracer developments hold the potential for in vivo markers of underlying pathology. Herein, we provide an overview of molecular imaging advances and how these approaches help us to understand PD and atypical parkinsonisms. © 2016 International Parkinson and Movement Disorder Society.

Keywords: FDG; PET; Parkinson's disease; acetylcholine; amyloid; atypical parkinsonism; dopamine; serotonin; tau.

PubMed Disclaimer

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- H1 Connect - Access expert opinions and insights on biomedical research.
- scite Smart Citations
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Molecular imaging to track Parkinson's disease and atypical parkinsonisms: New imaging frontiers

Affiliations

Molecular imaging to track Parkinson's disease and atypical parkinsonisms: New imaging frontiers

Authors

Affiliations

Abstract

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical